Switch theme
Sign up to access all valuation multiples
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
1969
105
LTM Revenue $25.8M
Last FY EBITDA -$54.9M
$73.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vaxart has a last 12-month revenue (LTM) of $25.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vaxart achieved revenue of $28.7M and an EBITDA of -$54.9M.
Vaxart expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vaxart valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $25.8M | XXX | $28.7M | XXX | XXX | XXX |
| Gross Profit | $25.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$54.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -191% | XXX | XXX | XXX |
| EBIT | -$68.0M | XXX | -$66.3M | XXX | XXX | XXX |
| EBIT Margin | -264% | XXX | -231% | XXX | XXX | XXX |
| Net Profit | -$68.6M | XXX | -$66.9M | XXX | XXX | XXX |
| Net Margin | -266% | XXX | -233% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Vaxart's stock price is $0.
Vaxart has current market cap of $98.6M, and EV of $73.4M.
See Vaxart trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $73.4M | $98.6M | XXX | XXX | XXX | XXX | $-0.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Vaxart has market cap of $98.6M and EV of $73.4M.
Vaxart's trades at 2.6x EV/Revenue multiple, and -1.3x EV/EBITDA.
Equity research analysts estimate Vaxart's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vaxart has a P/E ratio of -1.4x.
See valuation multiples for Vaxart and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $98.6M | XXX | $98.6M | XXX | XXX | XXX |
| EV (current) | $73.4M | XXX | $73.4M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBIT | -1.1x | XXX | -1.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.4x | XXX | -1.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVaxart's last 12 month revenue growth is -36%
Vaxart's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.9M for the same period.
Vaxart's rule of 40 is -1014% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vaxart's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vaxart and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -36% | XXX | -44% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -191% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1014% | XXX | -228% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 259% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 331% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vaxart acquired XXX companies to date.
Last acquisition by Vaxart was XXXXXXXX, XXXXX XXXXX XXXXXX . Vaxart acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vaxart founded? | Vaxart was founded in 1969. |
| Where is Vaxart headquartered? | Vaxart is headquartered in United States of America. |
| How many employees does Vaxart have? | As of today, Vaxart has 105 employees. |
| Who is the CEO of Vaxart? | Vaxart's CEO is Mr. Steven Lo. |
| Is Vaxart publicy listed? | Yes, Vaxart is a public company listed on NAS. |
| What is the stock symbol of Vaxart? | Vaxart trades under VXRT ticker. |
| When did Vaxart go public? | Vaxart went public in 1990. |
| Who are competitors of Vaxart? | Similar companies to Vaxart include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vaxart? | Vaxart's current market cap is $98.6M |
| What is the current revenue of Vaxart? | Vaxart's last 12 months revenue is $25.8M. |
| What is the current revenue growth of Vaxart? | Vaxart revenue growth (NTM/LTM) is -36%. |
| What is the current EV/Revenue multiple of Vaxart? | Current revenue multiple of Vaxart is 2.9x. |
| Is Vaxart profitable? | Yes, Vaxart is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
